AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie (ABBV) delivered impressive financial results for the first quarter of 2025. Investors responded enthusiastically, ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

A technological revolution is helping Scripps Research scientists see the molecules that undermine human health, from ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where AbbVie Inc.

Flyers urge consumers to take action beneficial to the pharmaceutical industry. But the campaign completely misses the bigger ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Roopal Thakkar; Executive Vice President, Research & Development, Chief Scientific Officer; AbbVie Inc Scott Reents; ...

The healthcare industry, an essential component of global well-being and economic resilience, is undergoing significant changes.

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology ...